Astepro Launch And Strong Cold Season Boost Bayer In Q3

The US OTC launch of reclassified nasal spray Astepro Allergy, in combination with “continuously elevated cold incidence rates,” helped to drive up Bayer's Consumer Health sales at a double-digit rate in Q3.

• Source: Alamy

Launching Astepro Allergy in the US following a successful Rx-to-OTC switch helped Bayer Consumer Health’s Allergy & Cold category post a double-digit rise in sales in the third quarter.

Allergy & Cold sales jumped by 32.6% to €342m ($344m) in Q3 as the gain delivered by Astepro was bolstered...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Rx-to-OTC Switch

More from Health